![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZNF865 |
Gene summary for ZNF865 |
![]() |
Gene information | Species | Human | Gene symbol | ZNF865 | Gene ID | 100507290 |
Gene name | zinc finger protein 865 | |
Gene Alias | ZNF865 | |
Cytomap | 19q13.42 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | P0CJ78 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
100507290 | ZNF865 | HCC1_Meng | Human | Liver | HCC | 1.55e-25 | 1.42e-02 | 0.0246 |
100507290 | ZNF865 | HCC2_Meng | Human | Liver | HCC | 4.60e-02 | 2.20e-02 | 0.0107 |
100507290 | ZNF865 | HCC1 | Human | Liver | HCC | 3.40e-20 | 1.90e+00 | 0.5336 |
100507290 | ZNF865 | HCC2 | Human | Liver | HCC | 1.16e-28 | 2.07e+00 | 0.5341 |
100507290 | ZNF865 | HCC5 | Human | Liver | HCC | 1.08e-21 | 1.95e+00 | 0.4932 |
100507290 | ZNF865 | S014 | Human | Liver | HCC | 3.32e-04 | 2.00e-01 | 0.2254 |
100507290 | ZNF865 | S015 | Human | Liver | HCC | 7.80e-08 | 3.34e-01 | 0.2375 |
100507290 | ZNF865 | S016 | Human | Liver | HCC | 2.35e-02 | 1.79e-01 | 0.2243 |
100507290 | ZNF865 | S028 | Human | Liver | HCC | 2.61e-05 | 2.44e-01 | 0.2503 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF865 | deletion | Frame_Shift_Del | novel | c.1278_1303delNNNNNNNNNNNNNNNNNNNNNNNNNN | p.Ala427GlyfsTer134 | p.A427Gfs*134 | P0CJ78 | protein_coding | TCGA-OL-A5RW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR | ||
ZNF865 | SNV | Missense_Mutation | novel | c.532N>A | p.Gly178Ser | p.G178S | P0CJ78 | protein_coding | tolerated_low_confidence(0.06) | unknown(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ZNF865 | SNV | Missense_Mutation | novel | c.1792N>A | p.Val598Met | p.V598M | P0CJ78 | protein_coding | tolerated(0.06) | possibly_damaging(0.865) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ZNF865 | SNV | Missense_Mutation | novel | c.1763N>A | p.Arg588His | p.R588H | P0CJ78 | protein_coding | deleterious(0.01) | possibly_damaging(0.809) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF865 | SNV | Missense_Mutation | novel | c.521N>T | p.Thr174Met | p.T174M | P0CJ78 | protein_coding | deleterious_low_confidence(0.01) | unknown(0) | TCGA-ZJ-AAX8-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
ZNF865 | SNV | Missense_Mutation | novel | c.428C>A | p.Pro143His | p.P143H | P0CJ78 | protein_coding | tolerated(0.28) | unknown(0) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF865 | SNV | Missense_Mutation | novel | c.1658N>A | p.Gly553Asp | p.G553D | P0CJ78 | protein_coding | deleterious(0.01) | unknown(0) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF865 | SNV | Missense_Mutation | novel | c.347N>A | p.Ser116Tyr | p.S116Y | P0CJ78 | protein_coding | deleterious_low_confidence(0.01) | unknown(0) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
ZNF865 | SNV | Missense_Mutation | novel | c.2624C>T | p.Pro875Leu | p.P875L | P0CJ78 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF865 | SNV | Missense_Mutation | novel | c.812N>A | p.Arg271His | p.R271H | P0CJ78 | protein_coding | tolerated(0.06) | unknown(0) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |